week 7 response 1

Peri men opau se

The transitional period before menopause when menstrual cycles become irregular.

Gradual decline in ovarian function and fluctuating estrogen/ progesterone levels.

Lifestyle modifications, symptom management, consider hormonal/non- hormonal therapies.

Me no pau se

The permanent cessation of menstruation for 12 consecutive months.

Ovarian follicular depletion → reduced estrogen production.

Patient education, bone health support, symptom relief strategies.

Post meno paus e

The phase after menopause has occurred.

Persistent low estrogen levels after final menstrual period.

Focus on long-term health: cardiovascular, bone, and vaginal health monitoring.

H ot fla sh es

Sudden feelings of heat, flushing, sweating, often with palpitations.

Estrogen withdrawal → hypothalamic thermoregulatory dysfunction.

Cool environment, layered clothing, possible HRT, non- hormonal meds (SSRIs, gabapentin).

Night sweats & Sleep disturbanc e

Excessive sweating during sleep, leading to insomnia or poor sleep quality.

Related to hot flashes disrupting sleep cycles.

Sleep hygiene, cooling measures, cognitive behavioral therapy, HRT if appropriate.

Irreg ular men ses

Unpredictable menstrual cycles (frequency, duration, flow).

Anovulatory cycles due to inconsistent ovarian hormone production.

Monitor for abnormal bleeding patterns, reassure, discuss contraception if needed.

Mood swings or irritabili ty

Emotional lability, increased anxiety, or depressive symptoms.

Hormonal fluctuations and sleep deprivation secondary to vasomotor symptoms.

Stress management, counseling, exercise, consider SSRIs/SNRIs if severe.

Vagi nal

Dryness, itching, Urogenital atrophy from decreased

estrogen → thinning of vaginal

Vaginal lubricants/ moisturizers, vaginal

SOAP NOTE

Patient: Barbara 
 Age: 48
 Gender: Female

SUBJECTIVE

Chief Complaint (CC): "My periods have become irregular, and I'm having hot flashes and vaginal dryness."

History of Present Illness (HPI): 
 Barbara is a 48-year-old G2P2 female who presents to the clinic to discuss new symptoms that have been developing over the past 6-8 months.

• Her cycles, previously regular at q28 days, are now unpredictable. Her last menstrual period (LMP) was 6 weeks ago. Prior to that, her cycles were approximately 21 days apart. She denies any heavy bleeding or intermenstrual spotting. She began experiencing "hot flashes" about 6 months ago. She describes them as a sudden feeling of intense heat in her face and chest, lasting 1-2 minutes, occurring 4-5 times per day. She also experiences night sweats 2-3 times per week, which occasionally disrupt her sleep. She notes progressive vaginal dryness over the past year, which has led to discomfort and pain with intercourse (dyspareunia). This has caused her to avoid intimacy at times. She reports a noticeable decrease in her libido over the past year, which she finds distressing.

Gynecologic History:

• Gravida/Para: G2 P2 (Two full-term spontaneous vaginal deliveries).

• Menarche: Age 13.

• Sexual Activity: Sexually active with one male partner (husband of 20 years).

• Contraception: Reports using condoms for contraception.

• Screening: Last Pap smear was 6 months ago, results were negative. A full STI panel performed at the same time was also negative. Pregnancy test performed in-office today is negative.

Decr ease libid o

Reduced interest in sexual activity.

Decline in estrogen and testosterone levels → changes in sexual response.

Open communication with partner, address physical symptoms, consider hormonal options.

Past Medical History (PMH): Unremarkable. No chronic illnesses. 
 Past Surgical History (PSH): None. 
 Medications: Multivitamin daily. 
 Allergies: No Known Drug Allergies (NKDA).

Family History: Mother experienced menopause at age 51. No family history of breast, ovarian, or uterine cancer. No family history of osteoporosis or premature cardiovascular disease.

Social History: Works as an office manager. Married, in a stable monogamous relationship. Has two daughters, ages 16 and 18. Denies tobacco use. Drinks 2-3 glasses of wine per week. Denies illicit drug use. Reports moderate stress related to work and family life. Patient participates in yoga classes 2-3x a week.

Review of Systems (ROS):

• Constitutional: Positive for hot flashes and night sweats. Denies fever or chills.

• Psychiatric: Positive for decreased libido. Denies significant anxiety, depression, or persistent mood swings.

• GU/Reproductive: Positive for irregular menses, vaginal dryness, and dyspareunia. Denies abnormal vaginal discharge, odor, or itching. Denies dysuria or urinary urgency.

• Skin: Positive for flushing during hot flashes. Denies other rashes or lesions.

• All other systems reviewed and are negative.

OBJECTIVE

Vitals:

• BP: 124/78 mmHg

• HR: 72 bpm

• RR: 16 rpm

• Temp: 98.4°F (36.9°C)

• BMI: 24.5 kg/m ²

General: Patient is a well-developed, well-nourished female, alert and oriented, in no acute distress.

Physical Exam:

• Thyroid: Neck is supple. Thyroid gland is non-palpable, without nodules or thyromegaly.

• Cardiovascular: Regular rate and rhythm. No murmurs, rubs, or gallops.

• Lungs: Clear to auscultation bilaterally.

• Abdomen: Soft, non-distended, non-tender. No organomegaly.

• Pelvic Exam:

o External Genitalia: Normal external female genitalia. No lesions or erythema.

o Speculum: Vaginal mucosa appears pale and thin with decreased rugation, consistent with atrophy. Cervix is pink, parous, with no lesions. Scant, clear vaginal discharge noted.

o Bimanual: Uterus is normal size, anteverted, mobile, and non-tender. Adnexa are non-tender and without palpable masses.

In-Office:

• Urine hCG: Negative.

ASSESSMENT

1. Perimenopause (N95.1): This is the primary diagnosis based on the patient's age and characteristic symptoms of irregular menses and vasomotor instability.

2. Genitourinary Syndrome of Menopause (GSM) (N95.21): Diagnosis supported by her symptoms of vaginal dryness and dyspareunia, and confirmed by physical exam findings of vaginal atrophy.

3. Female Sexual Interest/Arousal Disorder (F52.21): Secondary to hormonal changes and dyspareunia associated with perimenopause.

4. Encounter for contraceptive management (Z30.09): Patient remains at risk for pregnancy due to ongoing, albeit irregular, ovulation and requires discussion of continued contraception.

PLAN

1. Diagnostics:

a. Labs: Ordered TSH to rule out thyroid dysfunction as a contributor to menstrual irregularity. Ordered lipid panel and HbA1c for baseline cardiovascular and metabolic health screening.

2. Patient Education & Therapeutics:

a. General: Reassured the patient that her symptoms are characteristic of the normal menopausal transition. Provided educational pamphlets on perimenopause.

i. Counseled on lifestyle modifications: dressing in layers, avoiding triggers like caffeine and alcohol, maintaining a cool sleeping environment, and engaging in regular exercise.

ii. Discussed the option of Menopausal Hormone Therapy (MHT) as a highly effective treatment. Reviewed patient-specific risks and benefits, noting she is a good candidate given her age and lack of contraindications. Will defer decision until follow-up.

b. Genitourinary Syndrome of Menopause (GSM):

i. Rx: Recommended starting with an over-the-counter vaginal moisturizer (Replens) 2-3 times weekly and a water-based lubricant (Astroglide) with intercourse.

ii. Discussed low-dose vaginal estrogen (cream, tablet, or ring) as a highly effective and safe option if moisturizers are insufficient.

c. Contraception: Emphasized the need for reliable contraception until 12 months of amenorrhea have passed. Discussed continuing with condoms or transitioning to a low-dose combined OCP or a levonorgestrel IUD, which could also help regulate her cycle and manage symptoms.

3. Health Maintenance:

a. Counseled on the importance of adequate calcium (1200 mg/day) and Vitamin D (800-1000 IU/day) intake for bone health.

b. Encouraged continuation of a healthy diet and regular weight-bearing exercise.

c. Ensured she is up-to-date with age-appropriate health screenings, including mammogram and colonoscopy.

4. Follow-up:

a. Schedule a follow-up appointment in 3 months to discuss her response to initial lifestyle and non-prescription therapies, review lab results, and make a shared decision regarding the potential initiation of hormonal therapy if symptoms persist.